
51 - 200 employees
Founded 2006
🧬 Biotechnology
💊 Pharmaceuticals
💰 $60M Post-IPO Equity - Zevra Therapeutics on 2024-08
Biotechnology • Pharmaceuticals
Zevra Therapeutics is a purpose-driven biopharmaceutical company focused on developing and delivering life-changing therapeutics for people living with rare diseases. The company advances treatments for conditions such as Niemann-Pick disease type C, urea cycle disorders, and vascular Ehlers–Danlos through clinical trials, expanded access programs, and marketed products (including MIPLYFFA® and OLPRUVA®). Zevra emphasizes patient and caregiver partnerships, regulatory and investor communications, and building a pipeline of rare-disease therapies.
🔥 4 minutes ago
Medical Science Liaison engaging with healthcare professionals to advance understanding of rare diseases and Zevra’s portfolio. Building relationships and facilitating discussions aligned with US Medical strategy.
🏈 Alabama, Colorado, +7 more states – Remote
💰 $60M Post-IPO Equity - Zevra Therapeutics on 2024-08
⏰ Full Time
🟠 Senior